Nello Mainolfi via YouTube

At­las-backed Kymera grabs $102M as its pro­tein degra­da­tion tech­nol­o­gy heads in­to clin­ic

When Bruce Booth and Nel­lo Main­olfi start­ed plan­ning a pro­tein degra­da­tion com­pa­ny, the field was open and sparse, dot­ted with a cou­ple of hope­ful star­tups and larg­er play­ers mak­ing ex­plorato­ry for­ays. Booth called it a “broad new modal­i­ty with plen­ty of free­dom to op­er­ate across po­ten­tial­ly every ther­a­peu­tic area and dis­ease state.”

Four years lat­er, Kymera Ther­a­peu­tics is look­ing to be­come one of the first of what will like­ly be many pro­tein degra­da­tion com­pa­nies to en­ter the clin­ic. The com­pa­ny an­nounced $102 mil­lion in Se­ries C fund­ing and a plan to bring its lead drug tar­get­ing IRAK4 in­to the first tri­als by next year. Biotech­nol­o­gy Val­ue Fund and Red­mile Group led the round.

“We are at the cusp of tran­si­tion­ing from a re­search to a de­vel­op­ment or­ga­ni­za­tion — or, I should say, to a re­search and de­vel­op­ment or­ga­ni­za­tion,” Main­olfi, now the CEO, told End­points News.  “This fi­nanc­ing re­al­ly al­lows to build to­ward the con­cept of build­ing a ful­ly in­te­grat­ed biotech com­pa­ny around pro­tein degra­da­tion, which I think is prob­a­bly one of the most trans­for­ma­tive modal­i­ties.”

As of to­day, Kymera would like­ly be the sec­ond biotech to bring a pro­tein de­grad­er in­to the clin­ic. A year ago, Arv­inas – whose founder Craig Crews pub­lished some of the first work show­ing how pro­tein degra­da­tion could be drugged — brought what it be­lieves to be the first pro­tein de­grad­er in­to hu­man test­ing, an an­dro­gen re­cep­tor-tar­get­ing drug for prostate can­cer. C4 Ther­a­peu­tics, the oth­er ma­jor start­up that ex­ist­ed when Kymera launched, has part­ner­ships with Bio­gen, Roche, and Dana-Far­ber, but no ther­a­pies in the clin­ic.

The pro­tein is a ki­nase im­pli­cat­ed in sev­er­al can­cers. Small mol­e­cules can in­hib­it IRAK4’s prop­er­ties as a ki­nase, but the pro­tein al­so func­tions as a scaf­fold­ing pro­tein that helps build the my­d­do­some pro­tein com­plex. The com­plex is sup­posed to be ac­ti­vat­ed to re­spond to in­fec­tion but can some­times ac­ti­vate aber­rant­ly, lead­ing to in­flam­ma­to­ry or au­toim­mune dis­ease.

The idea be­hind pro­tein degra­da­tion is that in­stead of send­ing a mol­e­cule to block the pro­tein’s ki­nase bind­ing site — and leav­ing the rest of the pro­tein in­tact and func­tion­ing — re­searchers can re­move the pro­tein en­tire­ly. They do this by hi­jack­ing the body’s in­ter­nal sys­tem to re­move pro­teins that are mis­fold­ed or are in over­abun­dance. En­zymes called E3 lig­as­es tag un­want­ed pro­teins with a pro­tein called ubiq­ui­tin, like a gen­er­al pick­ing tar­gets for an air raid. Those tagged pro­teins are then tar­get­ed by pro­teas­es and un­fold­ed in the body’s mul­ti-step garbage dis­pos­al sys­tem.

Kymera us­es small mol­e­cules to drag E3 lig­as­es to the pro­tein it wants to elim­i­nate. Their pre­clin­i­cal re­search sug­gests re­mov­ing IRAK4 in this way will help treat a rare in­flam­ma­to­ry skin con­di­tion called hidradeni­tis sup­pu­ra­ti­va and B-cell lym­phomas, among oth­er dis­eases. They al­so have pro­grams tar­get­ing the tran­scrip­tion fac­tor STAT3, which is part of the JAK path­way.

Main­olfi said the gen­er­al con­cept had been ap­par­ent for years, but ad­vance­ments around 2016 made it look fea­si­ble.

“This is tech­nol­o­gy that has fas­ci­nat­ed me for years, but what was lack­ing were re­al­ly the chem­i­cal tools,” Main­olfi said.

Since then, Kymera has built up a plat­form they say dif­fer­en­ti­ates them from some of their com­peti­tors by us­ing in­for­mat­ics to iden­ti­fy new E3 lig­as­es and the best drugs in im­munol­o­gy and on­col­o­gy. And last year they signed a $70 mil­lion col­lab­o­ra­tion with Ver­tex. Main­olfi, who stepped in­to the CEO job in No­vem­ber af­ter Lau­rent Au­doly’s de­par­ture, said it helps them ap­ply their tech­nol­o­gy in in­di­ca­tions be­yond the two they’ve fo­cused on to date.

Even­tu­al­ly, he said, pro­tein degra­da­tion is go­ing to be every­where.

“When I look at pro­tein degra­da­tion, I look at a field just like an­ti­body or RNA ther­a­peu­tics 20 years ago,” Main­olfi said. “It is a field that will trans­form med­i­cine.”

Tesla and SpaceX founder Elon Musk gestures to the audience after being recognized by President Trump following the successful launch of a Falcon 9 rocket at the Kennedy Space Center. (via Getty Images)

Tes­la chief Elon Musk teams up with Covid-19 play­er Cure­Vac to build 'R­NA mi­cro­fac­to­ries'

Elon Musk has joined the global tech crusade now underway to revolutionize vaccine manufacturing — now aimed at delivering billions of doses of a new mRNA vaccine to fight Covid-19. And he’s cutting right to the front.

In a late-night tweet Wednesday, the Tesla chief announced:

Tesla, as a side project, is building RNA microfactories for CureVac & possibly others.

That’s not a lot to go on. But the tweet comes a year after Tesla’s German division in Grohmann and CureVac filed a patent on a “bioreactor for RNA in vitro transcription, a method for RNA in vitro transcription, a module for transcribing DNA into RNA and an automated apparatus for RNA manufacturing.” CureVac, in the meantime, has discussed a variety of plans to build microfactories that can speed up the whole process for a global supply chain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,600+ biopharma pros reading Endpoints daily — and it's free.

Elias Zerhouni (Photo by Vincent Isore/IP3/Getty Images)

Elias Zer­houni dis­cuss­es ‘am­a­teur hour’ in DC, the de­struc­tion of in­fec­tious dis­ease R&D and how we need to prep for the next time

Elias Zerhouni favors blunt talk, and in a recent discussion with NPR, the ex-Sanofi R&D and ex-NIH chief had some tough points to make regarding the pandemic response.

Rather than interpret them, I thought it would be best to provide snippets straight from the interview.

On the Trump administration response:

It was basically amateur hour. There is no central concept of operations for preparedness, for pandemics, period. This administration doesn’t want to or has no concept of what it takes to protect the American people and the world because it is codependent. You can’t close your borders and say, “OK, we’re going to be safe.” You’re not going to be able to do that in this world. So it’s a lack of vision, basically just a lack of understanding, of what it takes to protect the American people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,600+ biopharma pros reading Endpoints daily — and it's free.

Sec­ond death trig­gers hold on Astel­las' $3B gene ther­a­py biotech's lead pro­gram, rais­ing fresh con­cerns about AAV

Seven months after Astellas shelled out $3 billion to acquire the gene therapy player Audentes, the biotech company’s lead program has been put on hold following the death of 2 patients taking a high dose of their treatment. And there was another serious adverse event recorded in the study as well, with a total of 3 “older” patients in the study affected.

The incidents are derailing plans to file for a near-term approval, which had been expected right about now.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,600+ biopharma pros reading Endpoints daily — and it's free.

George Yancopoulos (Regeneron)

Re­gen­eron co-founder George Yan­copou­los of­fers a com­bat­ive de­fense of the po­lice at a high school com­mence­ment. It didn’t go well

Typically, the commencement speech at Yorktown Central School District in Westchester — like most high schools — is an opportunity to encourage students to face the future with confidence and hope. Regeneron president and co-founder George Yancopoulos, though, went a different route.

In a fiery speech, the outspoken billionaire defended the police against the “prejudice and bias against law enforcement” that has erupted around the country in street protests from coast to coast. And for many who attended the commencement, Yancopoulos struck the wrong note at the wrong time, especially when he combatively challenged someone for interrupting his speech with a honk for “another act of cowardness.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,600+ biopharma pros reading Endpoints daily — and it's free.

Dan Gold, MEI Pharma CEO

De­vel­op­ment part­ners at MEI, Helsinn dump a high-risk PhI­II AML study af­ter con­clud­ing it would fail sur­vival goal

Four years after Switzerland’s Helsinn put $25 million of cash on the table for an upfront and near-term milestone to take MEI Pharma’s drug pracinostat into a long-running Phase III trial for acute myeloid leukemia, the partners are walking away from a clinical pileup.

The drug — an HDAC inhibitor — failed to pass muster during a futility analysis, as researchers concluded that pracinostat combined with azacitidine wasn’t going to outperform the control group in the pivotal.

Pfiz­er shares surge on pos­i­tive im­pact of their mR­NA Covid-19 vac­cine — part­nered with BioN­Tech — in an ear­ly-stage study

Pfizer and their partners at the mRNA specialist BioNTech have published the first glimpse of biomarker data from an early-stage study spotlighting the “robust immunogenicity” triggered by their Covid-19 vaccine, which is one of the leaders in the race to vanquish the global pandemic.

Researchers selected 45 healthy volunteers 18-55 years of age for the study. They were randomized to receive 2 doses, separated by 21 days, of 10 µg, 30 µg, or 100 µg of BNT162b1, “a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD.” Their responses were compared against the effect of a natural, presumably protective defense offered by a regular infection.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,600+ biopharma pros reading Endpoints daily — and it's free.

An ex­pe­ri­enced biotech is stitched to­geth­er from transpa­cif­ic parts, with 265 staffers and a fo­cus on ‘new bi­ol­o­gy’

Over the past few years, different teams at a pair of US-based biotechs and in labs in Japan have labored to piece together a group of cancer drug programs, sharing a single corporate umbrella with research colleagues in Japan. But now their far-flung operations have been knit together into a single unit, creating a pipeline with 10 cancer drug development programs — going from early-stage right into Phase III — and a host of discovery projects managed by a collective staff of some 265 people.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,600+ biopharma pros reading Endpoints daily — and it's free.

Joseph Kim, Inovio CEO (Andrew Harnik, AP Images)

Pos­i­tive Covid-19 vac­cine da­ta? New mouse study? OWS in­clu­sion? Yep, but some­how, the usu­al tid­bits from In­ovio back­fire

You don’t go more than 40 years in biotech without ever getting a product to market unless you can learn the art of writing a promotional press release. And Inovio captures the prize in baiting the hook.

Tuesday morning Inovio, which has been struggling to get its Covid-19 vaccine lined up for mass manufacturing, put out a release that touched on virtually every hot button in pandemic PR.

There was, first and foremost, an interim snapshot of efficacy from their Phase I program for INO-4800.

Jan van de Winkel, Genmab CEO

Seat­tle Ge­net­ics, Gen­mab turn on TV for a high­light reel in cer­vi­cal can­cer — but a ri­val biotech promis­es a bet­ter show

Seattle Genetics $SGEN and their partners at Genmab $GMAB polished up some positive Phase II numbers for their antibody drug conjugate tisotumab vedotin — you can call it TV — for recurrent cervical cancer. And while they mapped out a shortcut to a potential quick approval, the big challenge for this team is being presented by a rival biotech which muscled its way into the spotlight for the same indication a year ago.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 84,600+ biopharma pros reading Endpoints daily — and it's free.